Goodbye CFDA, Hello MRA: China Overhauls Regulatory Bodies
Executive Summary
China proposes to merge its top drug regulator into new combined body, and creates a medical reimbursement agency in move viewed as sign of strengthening regulatory oversight.
You may also be interested in...
Bigger, Bolder, SMAR: Decoding China's All-In-One Regulatory Agency
A new era began April 10 with disappearance of China FDA and kickoff of State Administration for Market Regulation (SMAR), the so-called 'One-Stop' regulatory agency. Will the CFDA's innovation-encouraging policies continue? How will the new agency balance innovation and enforcement? Pink Sheet offers preliminary answers to these key questions and decode the new SMAR from five important aspects.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.